DXCM
Health Care

DexCom, Inc.

DXCM
Since 1999

Headquarters:

CA, United States

Exchange:

NASDAQ

Industry:

Medical Devices

Number of Employees:

9.50K

Current Fiscal Year:

2024

Market Cap:

27.88B

Price per Share:

$71.38

Quarterly Dividend per Share:

Year-to-date Performance:
-9.0701%
Dividend Yield:
%
Price-to-book Ratio:
14.09
Trailing P/E Ratio:
40.95

Price History

Latest Prices

DateOpenHighLowClose
2025-04-3070.66571.5769.7571.38
2025-04-2971.27571.4670.2971.3
2025-04-2872.2772.670.573171.18
2025-04-2570.8572.2870.35571.66
2025-04-2467.7970.9867.54570.78

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Financial Performance

2024 Revenue:3.95B

Detailed view of quarterly revenue

2024 Net Income:680.80M

Detailed view of quarterly net income

2024 Free Cash Flow:535.00M

Overview of free cash flow for the quarter

Annual Revenue Comparison

Compares total annual revenues

Similar Companies